A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1

Total Enrollment

252 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-12-04

Study Completion Date

2026-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will assess the safety of the investigational drug CRB-913 and how it is processed in the body.

The study has two parts: Part 1 will measure drug levels in healthy adults after taking CRB-913 tablets, and Part 2 will compare three doses of CRB-913 with placebo to evaluate safety, effects on body weight, and drug levels in the blood.

Part 2 is blinded, meaning participants, study doctors, and the sponsor will not know which treatment is given.

Participants in Part 2 will take study treatment for 12 weeks and will be followed for 28 days after treatment ends.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

CRB-913 is a novel cannabinoid receptor type 1 (CB1) inverse agonist (CB1-IA) that is being developed for once-daily treatment of obesity.

This study will look at how the investigational drug CRB-913 behaves in the body and how it affects body weight.

The study has two parts:

Part 1 will include healthy adult participants. They will receive CRB-913 in tablet form. Researchers will measure how much of the drug enters the bloodstream and how long it stays there.

Part 2 will include participants who will receive one of three different doses of CRB-913 or a placebo (a tablet with no active drug). This part of the study will look at the safety of CRB-913 and its effects on body weight. Researchers will also measure the amount of CRB-913 in the blood.

Part 2 is blinded, which means that participants, study doctors, and the study sponsor will not know who is receiving CRB-913 or placebo.

All participants in Part 2 will take their assigned study tablets for 12 weeks, followed by a 28-day follow-up period after treatment ends.

The information collected in this study will help determine whether CRB-913 is safe, how the body processes it, and whether it may help with weight-related outcomes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obese But Otherwise Healthy Participants

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Obesity Body Weight Nutritional and Metabolic Diseases Metabolic Diseases Endocrine System Diseases Overweight Nutrition Disorders Cannabinoid-1 receptor inverse agonist

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Part 1 is open label. Part 2 is double blind.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Part 1: PK Lead-in

Primary Treatment Period (Day 1): Participants will receive a single dose of CRB-913. Following Part 1 of the study Part 2 will open for recruitment.

Safety Follow-up Period: Participants who complete or discontinue the primary treatment period are followed for safety for 28 days. No treatment is administered during this period.

Group Type EXPERIMENTAL

CRB-913

Intervention Type DRUG

Administered QD

Part 2: CRB-913 low dose

Primary Treatment Period (Day 0-Day 85): Participants will receive CRB-913 low dose which is maintained up to day 85.

Safety Follow-up Period: Participants who complete or discontinue the primary treatment period are followed for safety for 28 days. No treatment is administered during this period.

Group Type EXPERIMENTAL

CRB-913

Intervention Type DRUG

Administered QD

Part 2: CRB-913 Medium Dose

Primary Treatment Period (Day 0-Day 85): Participants will receive CRB-913 starting at low dose for 14 days and increasing to medium dose at day 15 which is maintained up to day 85.

Safety Follow-up Period: Participants who complete or discontinue the primary treatment period are followed for safety for 28 days. No treatment is administered during this period.

Group Type EXPERIMENTAL

CRB-913

Intervention Type DRUG

Administered QD

Part 2: CRB-913 High Dose

Primary Treatment Period (Day 0 - Day 85): Participants will receive CRB-913 starting at low dose for 14 days, increasing to medium dose at day 15 for 14 days and then increased to high dose at day 29 which is maintained up to day 85.

Safety Follow-up Period: Participants who complete or discontinue the primary treatment period are followed for safety for 28 days. No treatment is administered during this period.

Group Type EXPERIMENTAL

CRB-913

Intervention Type DRUG

Administered QD

Part 2: Placebo

Primary Treatment Period (Day 0-Day 85): Participants will receive CRB-913 matching placebo which is maintained up to day 85.

Safety Follow-up Period: Participants who complete or discontinue the primary treatment period are followed for safety for 28 days. No treatment is administered during this period.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Administered QD

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CRB-913

Administered QD

Intervention Type DRUG

Placebo

Administered QD

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Part 1: Participants with BMI 18.0-25.0 kg/m²
* Part 2: Obese participants with BMI ≥30 kg/m²

Exclusion Criteria

* Significant liver disease or moderate-severe hepatic impairment
* History of seizures, epilepsy, or intracranial surgery
* Diabetes mellitus (Type 1 or Type 2), except gestational
* Bariatric surgery or \>5 kg weight change in past 3 months
* Recent use (within 3 months) of GLP-1 agonists or other weight-loss medications
* Major depression within 2 years.
* Any history of suicidal ideation/attempt
* Severe psychiatric disorders (e.g., schizophrenia, bipolar disorder)
* Elevated screening scores: PHQ-9 \>4, GAD-7 \>4, or positive C-SSRS Items 1-2
* Active or recent (within 5 years) malignancy (exceptions: in situ and fully resected nonmelanoma skin cancer)
* Abnormal thyroid function: TSH \>6 mIU/L unless stable on replacement therapy
* QTc \>470 msec (females) or \>450 msec (males) or history of long QT syndrome
* Use of systemic corticosteroids or unstable chronic medications affecting BP, lipids, or glucose
* Use of CYP3A4 substrates or strong P-gp substrates/inhibitors
* Investigational drug use within 28 days
* Prior exposure to CRB-913 or other CB1 inverse agonists/antagonists
* Substance abuse history
* Pregnancy, breastfeeding, or unwillingness to use highly effective contraception
* Positive drug or alcohol screen
* Any condition that, in the investigator's judgment, makes participation unsafe or non-feasible

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Leela Vrishabhendra, MD

Role: PRINCIPAL_INVESTIGATOR

Medpace Clinical Pharmacology

Locations

Explore where the study is taking place and check the recruitment status at each participating site.